Intrinsiqq
Sol-Gel Technologies Ltd. logo

Sol-Gel Technologies Ltd. Quality Score

SLGL

⊜ Compare
Quality65

Growth remains strong (avg 100/100), but valuation is pulling the composite down (avg 20/100).

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-30.1x

Negative earnings, no valuation support

Cash Flow Multiple
40/100
668.6x

Above 30x, cash flow yield is thin

Revenue Growth
100/100
70.9%

Above 10% CAGR, strong compounder

Cash Flow Growth
60/100
Just turned +

Recently turned FCF-positive, capex cycle finishing, CAGR not yet meaningful

Business Quality & Capital Allocation

Share Dilution
100/100
-88.0%

Shrinking >2%, active buybacks

Margin Trend
100/100
+379.5pp

Expanded 3+pp, strong improvement

Capital Structure
100/100
-$23M

Net cash position, no leverage concern

2022
$21.0M
$772000
2023
$28.0M
$2.00M
2024
$24.0M
$1.00M
2025
$24.0M
$991000
CashDebt
Return on Capital
0/100
-22.1%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Sol-Gel Technologies (SLGL) quality: score, margins and returns

Sol-Gel Technologies (SLGL) scores 65/100 on Intrinsiqq's quality score (a solid business), a weighted blend of 6 metrics each scored 0 to 100, on -38.9% operating margins and -22.1% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Sol-Gel Technologies (SLGL) a high-quality business?+

Sol-Gel Technologies scores 65 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which rates it a solid business on these measures. Recent figures include a -38.9% operating margin and a -22.1% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Sol-Gel Technologies's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from SLGL's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Sol-Gel Technologies scores well and where it falls behind.

What is Sol-Gel Technologies's return on invested capital (ROIC)?+

Sol-Gel Technologies earns about -22.1% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to SLGL's margins and growth on this scorecard to judge durability.

How profitable is Sol-Gel Technologies?+

Sol-Gel Technologies runs an operating margin of about -38.9% and a net margin of about -31.6%. Revenue has grown at roughly 17.2% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-K filed 19 Mar 2026, covering the period ending 31 Dec 2025, as reported to the SEC. Data last refreshed 17 Apr 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Pharmaceutical Preparations · Pick stocks to compare with SLGL

CompareIntrinsic value
EVFMEvofem Biosciences Inc.
$0.01+0.00%15
SCYXScynexis, Inc.
$3.84-2.54%40
QUREuniQure N.V.
$23.07-3.35%10
CRNXCrinetics Pharmaceuticals Inc.
No recent price40
TNXPTonix Pharmaceuticals Holding Corp
$5.11-1.54%40
NAMSNewAmsterdam Pharma Co. N.V.
$20.93+5.18%10
NEUPNeuphoria Therapeutics Inc.
$2.98-0.33%10
PYXSPyxis Oncology, Inc.
$1.66+1.22%10

Held by ETFs

SLGL is in 1 US ETF. The largest of them, with SLGL's weight in each:

Spot a number that looks wrong? Check it in SLGL's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing SLGL

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.